Real-life LDL-C treatment goals achievement in patients with heterozygous familial hypercholesterolemia in the Czech Republic and Slovakia: Results of the PLANET registry.

[1]  P. Shah,et al.  Efficacy and Safety of Alirocumab in High-Risk Patients With Clinical Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from 5 Placebo-Controlled ODYSSEY Trials). , 2018, The American journal of cardiology.

[2]  E. Sijbrands,et al.  Cardiovascular risk in patients with familial hypercholesterolemia using optimal lipid-lowering therapy. , 2018, Journal of clinical lipidology.

[3]  Emily C. O'Brien,et al.  Health disparities among adult patients with a phenotypic diagnosis of familial hypercholesterolemia in the CASCADE-FH™ patient registry. , 2017, Atherosclerosis.

[4]  K. Poh,et al.  Cholesterol target value attainment and lipid-lowering therapy in patients with stable or acute coronary heart disease: Results from the Dyslipidemia International Study II. , 2017, Atherosclerosis.

[5]  L. Pérez de Isla,et al.  Attainment of LDL Cholesterol Treatment Goals in Children and Adolescents With Familial Hypercholesterolemia. The SAFEHEART Follow-up Registry. , 2017, Revista espanola de cardiologia.

[6]  L. P. D. Isla,et al.  Consecución de objetivos terapéuticos de colesterol LDL en niños y adolescentes con hipercolesterolemia familiar. Registro longitudinal SAFEHEART , 2017 .

[7]  L. Fajkusová,et al.  Familial hypercholesterolemia in the Czech Republic: more than 17 years of systematic screening within the MedPed project. , 2017, Physiological research.

[8]  A. Hoes,et al.  2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Assocciation for Cardiovascular Prevention , 2016, Atherosclerosis.

[9]  G. Watts,et al.  Mutations causative of familial hypercholesterolaemia: screening of 98 098 individuals from the Copenhagen General Population Study estimated a prevalence of 1 in 217. , 2016, European heart journal.

[10]  G. Watts,et al.  Attainment of LDL-Cholesterol Treatment Goals in Patients With Familial Hypercholesterolemia: 5-Year SAFEHEART Registry Follow-Up. , 2016, Journal of the American College of Cardiology.

[11]  Jennifer G. Robinson,et al.  Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. , 2015, The New England journal of medicine.

[12]  Improve-It Investigators.  Ezetimibe added to statin therapy after acute coronary syndromes , 2015 .

[13]  Jennifer G. Robinson,et al.  Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. , 2015, The New England journal of medicine.

[14]  Jennifer G. Robinson,et al.  2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2014, Circulation.

[15]  N. Wong.  Faculty Opinions recommendation of 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2014 .

[16]  A. Tonkin.  Faculty Opinions recommendation of Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. , 2014 .

[17]  Thomas B Repas,et al.  Preventing Early Cardiovascular Death in Patients With Familial Hypercholesterolemia , 2014, The Journal of the American Osteopathic Association.

[18]  Catherine Boileau,et al.  Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease , 2013, European heart journal.

[19]  G. Watts,et al.  Familial hypercholesterolemia in the danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication. , 2012, The Journal of clinical endocrinology and metabolism.

[20]  M. Taskinen,et al.  'Ten Commandments' from the 2016 ESC/EAS Guidelines for the management of dyslipidaemias. , 2011, European heart journal.

[21]  P. Kolh,et al.  ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). , 2011, European heart journal.

[22]  E. Guallar,et al.  Clinical characteristics and evaluation of LDL-cholesterol treatment of the Spanish Familial Hypercholesterolemia Longitudinal Cohort Study (SAFEHEART) , 2011, Lipids in Health and Disease.

[23]  J. Kastelein,et al.  Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in The Netherlands. , 2010, Atherosclerosis.

[24]  M. Epstein,et al.  Guidelines for good pharmacoepidemiology practices (GPP) , 2008 .

[25]  L. Wsólová,et al.  Familial defective apolipoprotein B-100 in Slovakia: are differences in prevalence of familial defective apolipoprotein B-100 explained by ethnicity? , 2007, Atherosclerosis.

[26]  P. Sager,et al.  Further reduction of low-density lipoprotein cholesterol and C-reactive protein with the addition of ezetimibe to maximum-dose rosuvastatin in patients with severe hypercholesterolemia. , 2007, Journal of clinical lipidology.

[27]  S. Humphries,et al.  Mutational analysis in UK patients with a clinical diagnosis of familial hypercholesterolaemia: relationship with plasma lipid traits, heart disease risk and utility in relative tracing , 2006, Journal of Molecular Medicine.

[28]  L. Iacoviello,et al.  Lipid levels and their genetic regulation in patients with familial hypercholesterolemia and familial defective apolipoprotein B-100: the MEDPED Slovakia Project. , 2003, Atherosclerosis. Supplements.

[29]  Risk of fatal coronary heart disease in familial hypercholesterolaemia. Scientific Steering Committee on behalf of the Simon Broome Register Group. , 1991, BMJ.

[30]  R. Califf,et al.  Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. , 2015, The New England journal of medicine.

[31]  M. Taskinen,et al.  [ESC/EAS Guidelines for the management of dyslipidaemias]. , 2011, Revista espanola de cardiologia.